FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065249270> ?p ?o ?g. }

• W2065249270 endingPage "556" @default.
• W2065249270 startingPage "550" @default.
• W2065249270 abstract "Purpose We have developed nanoparticle γ-cyclodextrin dexamethasone (DexNP) and dorzolamide (DorzNP) eye drops that provide sustained high drug concentrations on the eye surface. To test these characteristics, we measured dexamethasone and dorzolamide levels in tear fluid in humans following eye drop administration. Methods Concentration of dexamethasone was measured by mass spectrometry. One drop of DexNP was instilled into one eye. Tear fluid was sampled with microcapillary pipettes at seven time-points after drop instillation. Control eyes received Maxidex® (dexamethasone). The same procedure was performed for dorzolamide with DorzNP and Trusopt®. Results Six subjects were included in each group. The peak concentration (μg/ml ± standard deviation) of dexamethasone for DexNP eye drops (636.6 ± 399.1) was up to 19-fold higher than with Maxidex® (39.3 ± 18.9) (p < 0.001). At 4 hr, DexNP was still 10 times higher than Maxidex®. In addition, DexNP resulted in about 30-fold higher concentration of dissolved dexamethasone in the tear fluid of extended time period allowing more drug to partition into the eye tissue. The overall concentration of dorzolamide was about 50% higher for DorzNP (59.5 ± 76.9) than Trusopt® (40.0 ± 76.7) (p < 0.05). Conclusion The results indicate high and extended concentration of dissolved dexamethasone with DexNP, which can explain the greater and longer lasting effect of dexamethasone in the cyclodextrin nanoparticle drug delivery platform. Dexamethasone seems to fit the cyclodextrin nanoparticle suspension drug delivery platform with longer duration and higher concentrations in tear fluid than available commercial drops, while dorzolamide is less suitable." @default.
• W2065249270 created "2016-06-24" @default.
• W2065249270 creator A5005050724 @default.
• W2065249270 creator A5018640108 @default.
• W2065249270 creator A5037180334 @default.
• W2065249270 creator A5053846920 @default.
• W2065249270 creator A5062520026 @default.
• W2065249270 creator A5068216380 @default.
• W2065249270 creator A5069213160 @default.
• W2065249270 date "2013-12-24" @default.
• W2065249270 modified "2023-10-17" @default.
• W2065249270 title "Kinetics of<i>γ</i>-cyclodextrin nanoparticle suspension eye drops in tear fluid" @default.
• W2065249270 cites W1491055753 @default.
• W2065249270 cites W1558570404 @default.
• W2065249270 cites W1697337825 @default.
• W2065249270 cites W1965020544 @default.
• W2065249270 cites W1966341577 @default.
• W2065249270 cites W1968230157 @default.
• W2065249270 cites W1996743648 @default.
• W2065249270 cites W2001570423 @default.
• W2065249270 cites W2005090059 @default.
• W2065249270 cites W2008221802 @default.
• W2065249270 cites W2034358901 @default.
• W2065249270 cites W2052198418 @default.
• W2065249270 cites W2057044401 @default.
• W2065249270 cites W2059195099 @default.
• W2065249270 cites W2066368129 @default.
• W2065249270 cites W2069972483 @default.
• W2065249270 cites W2079159055 @default.
• W2065249270 cites W2084102641 @default.
• W2065249270 cites W2091457816 @default.
• W2065249270 cites W2092865989 @default.
• W2065249270 cites W2093470897 @default.
• W2065249270 cites W2094486190 @default.
• W2065249270 cites W2146872605 @default.
• W2065249270 cites W2156932023 @default.
• W2065249270 cites W2161279821 @default.
• W2065249270 doi "https://doi.org/10.1111/aos.12334" @default.
• W2065249270 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24373641" @default.
• W2065249270 hasPublicationYear "2013" @default.
• W2065249270 type Work @default.
• W2065249270 sameAs 2065249270 @default.
• W2065249270 citedByCount "38" @default.
• W2065249270 countsByYear W20652492702013 @default.
• W2065249270 countsByYear W20652492702014 @default.
• W2065249270 countsByYear W20652492702015 @default.
• W2065249270 countsByYear W20652492702016 @default.
• W2065249270 countsByYear W20652492702017 @default.
• W2065249270 countsByYear W20652492702018 @default.
• W2065249270 countsByYear W20652492702020 @default.
• W2065249270 countsByYear W20652492702021 @default.
• W2065249270 countsByYear W20652492702022 @default.
• W2065249270 countsByYear W20652492702023 @default.
• W2065249270 crossrefType "journal-article" @default.
• W2065249270 hasAuthorship W2065249270A5005050724 @default.
• W2065249270 hasAuthorship W2065249270A5018640108 @default.
• W2065249270 hasAuthorship W2065249270A5037180334 @default.
• W2065249270 hasAuthorship W2065249270A5053846920 @default.
• W2065249270 hasAuthorship W2065249270A5062520026 @default.
• W2065249270 hasAuthorship W2065249270A5068216380 @default.
• W2065249270 hasAuthorship W2065249270A5069213160 @default.
• W2065249270 hasBestOaLocation W20652492701 @default.
• W2065249270 hasConcept C118487528 @default.
• W2065249270 hasConcept C126322002 @default.
• W2065249270 hasConcept C185592680 @default.
• W2065249270 hasConcept C2776727336 @default.
• W2065249270 hasConcept C2777625524 @default.
• W2065249270 hasConcept C2778073030 @default.
• W2065249270 hasConcept C2779433975 @default.
• W2065249270 hasConcept C2780401358 @default.
• W2065249270 hasConcept C2781092963 @default.
• W2065249270 hasConcept C43617362 @default.
• W2065249270 hasConcept C71924100 @default.
• W2065249270 hasConceptScore W2065249270C118487528 @default.
• W2065249270 hasConceptScore W2065249270C126322002 @default.
• W2065249270 hasConceptScore W2065249270C185592680 @default.
• W2065249270 hasConceptScore W2065249270C2776727336 @default.
• W2065249270 hasConceptScore W2065249270C2777625524 @default.
• W2065249270 hasConceptScore W2065249270C2778073030 @default.
• W2065249270 hasConceptScore W2065249270C2779433975 @default.
• W2065249270 hasConceptScore W2065249270C2780401358 @default.
• W2065249270 hasConceptScore W2065249270C2781092963 @default.
• W2065249270 hasConceptScore W2065249270C43617362 @default.
• W2065249270 hasConceptScore W2065249270C71924100 @default.
• W2065249270 hasFunder F4320324618 @default.
• W2065249270 hasIssue "6" @default.
• W2065249270 hasLocation W20652492701 @default.
• W2065249270 hasLocation W20652492702 @default.
• W2065249270 hasOpenAccess W2065249270 @default.
• W2065249270 hasPrimaryLocation W20652492701 @default.
• W2065249270 hasRelatedWork W132053806 @default.
• W2065249270 hasRelatedWork W1989108604 @default.
• W2065249270 hasRelatedWork W1990941510 @default.
• W2065249270 hasRelatedWork W2040818997 @default.
• W2065249270 hasRelatedWork W2052029677 @default.
• W2065249270 hasRelatedWork W2065249270 @default.
• W2065249270 hasRelatedWork W2075150324 @default.
• W2065249270 hasRelatedWork W2748952813 @default.

• next